HC Wainwright Issues Negative Outlook for NovoCure Earnings

NovoCure Limited (NASDAQ:NVCR) – Equities researchers at HC Wainwright lowered their Q1 2026 earnings per share (EPS) estimates for shares of NovoCure in a research report issued on Thursday, February 5th. HC Wainwright analyst E. Bodnar now expects that the medical equipment provider will post earnings of ($0.50) per share for the quarter, down from their prior forecast of ($0.34). HC Wainwright has a “Buy” rating and a $39.00 price target on the stock. The consensus estimate for NovoCure’s current full-year earnings is ($1.30) per share. HC Wainwright also issued estimates for NovoCure’s Q2 2026 earnings at ($0.32) EPS, FY2026 earnings at ($1.62) EPS and FY2028 earnings at ($0.35) EPS.

NVCR has been the topic of a number of other research reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of NovoCure in a research report on Thursday, January 22nd. JPMorgan Chase & Co. reduced their price objective on NovoCure from $25.00 to $23.00 and set a “neutral” rating on the stock in a research note on Monday, October 27th. Wedbush reiterated a “neutral” rating and issued a $18.00 price objective on shares of NovoCure in a report on Thursday, January 15th. Finally, Evercore set a $20.00 target price on NovoCure in a report on Monday, January 5th. Three research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $25.50.

NovoCure Trading Up 0.5%

NVCR stock opened at $10.14 on Monday. The company has a market capitalization of $1.14 billion, a PE ratio of -6.30 and a beta of 0.73. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.50 and a current ratio of 1.55. NovoCure has a one year low of $9.82 and a one year high of $23.18. The company’s 50 day moving average price is $12.95 and its two-hundred day moving average price is $12.64.

Institutional Investors Weigh In On NovoCure

Institutional investors and hedge funds have recently made changes to their positions in the company. Mach 1 Financial Group LLC purchased a new position in NovoCure in the 4th quarter worth about $189,000. Larson Financial Group LLC grew its holdings in NovoCure by 25.2% during the 4th quarter. Larson Financial Group LLC now owns 5,133 shares of the medical equipment provider’s stock valued at $66,000 after buying an additional 1,033 shares in the last quarter. Handelsbanken Fonder AB increased its holdings in NovoCure by 14.4% in the 4th quarter. Handelsbanken Fonder AB now owns 37,323 shares of the medical equipment provider’s stock valued at $483,000 after acquiring an additional 4,700 shares during the last quarter. ProShare Advisors LLC grew its holdings in NovoCure by 10.0% during the 4th quarter. ProShare Advisors LLC now owns 23,493 shares of the medical equipment provider’s stock valued at $304,000 after buying an additional 2,136 shares in the last quarter. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al raised its stake in NovoCure by 16.1% during the fourth quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 24,217 shares of the medical equipment provider’s stock valued at $313,000 after purchasing an additional 3,350 shares in the last quarter. Institutional investors own 84.61% of the company’s stock.

About NovoCure

NovoCure is a global oncology company pioneering Tumor Treating Fields (TTFields), a novel anti-mitotic therapy for solid tumors. The company’s non-invasive treatment platforms deliver low-intensity, alternating electric fields designed to disrupt cancer cell division. NovoCure’s approach offers an alternative modality to complement existing therapies in oncology, with a focus on hard-to-treat malignancies.

Founded in 2000 and headquartered in Haifa, Israel, NovoCure maintains a second operational center in Portsmouth, New Hampshire.